All In Biotech

Drug Trial Radar · NCT00764907

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: Jul 8, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 4,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,000

Planned (sponsor's estimate)

Start

Nov 2002

Primary completion

Oct 2007

Sponsor

Lead sponsor
University Hospital, MotolAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. A donor stem cell transplant may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving combination chemotherapy before the transplant helps stop the growth of cancer cells and stop the patient's immune system from rejecting the donor's stem cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying different risk-adjusted combination chemotherapy regimens in treating young patients with acute lymphoblastic leukemia.

Conditions

  • Leukemia

Interventions

  • asparaginaseDrug

    Given IV during reinduction

  • cyclophosphamideDrug

    Given IV during reinduction

  • cytarabineDrug

    Given IV during reinduction

  • daunorubicin hydrochlorideDrug

    Given IV during reinduction

  • dexamethasoneDrug

    Given IV or orally during reinduction

  • doxorubicin hydrochlorideDrug

    Given IV during reinduction

  • etoposideDrug

    Given IV during reinduction

  • ifosfamideDrug

    Given IV during reinduction

  • leucovorin calciumDrug

    Given IV during reinduction

  • mercaptopurineDrug

    Given orally during reinduction

  • methotrexateDrug

    Given orally during reinduction

  • prednisoneDrug

    Given intrathecally during reinduction

  • thioguanineDrug

    Given orally during reinduction

  • vincristine sulfateDrug

    Given IV during reinduction

  • vindesineDrug

    Given IV during reinduction

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival
  2. Event-free survival
  3. Overall survival

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Motol

    Prague, Czechia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.